PureTech Health

Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily. It was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Karuna Pharmaceuticals, Inc. engages in development of drugs for the treatment of schizophrenia. The company was incorporated in 2009 and is based in Boston, Massachusetts.

Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily. It was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Karuna Pharmaceuticals, Inc. engages in development of drugs for the treatment of schizophrenia. The company was incorporated in 2009 and is based in Boston, Massachusetts.

resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases.The Company develops medicines and therapies to treat aging-related diseases and conditions such as cancer, heart disease, neurodegenerative diseases, and diabetes mellitus. resTORbio serves clients in the State of Massachusetts.

Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily. It was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Akili Interactive Labs, Inc. is a digital medicine company based in Boston, Massachusetts, that develops innovative platform technology to enhance cognitive abilities through video game-like experiences. Incorporated in 2011, the company focuses on creating clinically validated cognitive therapeutics, assessments, and diagnostics that can be prescribed and monitored by physicians remotely. Akili's cognitive engine supports multiple clinical game versions designed for patient engagement and remote data capture. Its proprietary adaptive mechanics allow the software to personalize to each patient's ability level automatically, without requiring clinician input. This approach aims to provide a cost-effective alternative to traditional medical treatments, making advanced cognitive therapies accessible to patients regardless of their location.

Gelesis, Inc. is a biotechnology company focused on developing therapies for gastrointestinal-related chronic diseases, particularly obesity and type 2 diabetes. Utilizing a mechanobiology technology platform, Gelesis creates innovative products aimed at weight management. Its lead product, Gelesis100, is an orally administered smart pill composed of hydrogel particles that expand in the gastrointestinal tract, promoting a feeling of fullness and aiding in calorie reduction. This product is designed to be safe, having materials recognized as safe by regulatory authorities. In addition to Gelesis100, the company has a pipeline of potential therapies targeting conditions such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic idiopathic constipation. Founded in 2006, Gelesis is based in Boston, Massachusetts.

Tal Medical, Inc. is a clinical stage neuroscience company based in Boston, Massachusetts, focused on developing non-invasive neurostimulation treatments for psychiatric and neurological disorders. Founded in 2010, the company specializes in Low Field Magnetic Stimulation (LFMS), a technology designed to modulate brain circuitry associated with major depressive disorder and bipolar depression. By utilizing this innovative approach, Tal Medical aims to address significant unmet clinical needs where existing treatments often have limited effectiveness and undesirable side effects. The LFMS technology, initially developed at McLean Hospital, enables clinicians to target hyperactive neural circuits in patients, offering a potential advancement in the management of these debilitating conditions. Tal Medical operates as a subsidiary of PureTech Health PLC.

Gelesis, Inc. is a biotechnology company focused on developing therapies for gastrointestinal-related chronic diseases, particularly obesity and type 2 diabetes. Utilizing a mechanobiology technology platform, Gelesis creates innovative products aimed at weight management. Its lead product, Gelesis100, is an orally administered smart pill composed of hydrogel particles that expand in the gastrointestinal tract, promoting a feeling of fullness and aiding in calorie reduction. This product is designed to be safe, having materials recognized as safe by regulatory authorities. In addition to Gelesis100, the company has a pipeline of potential therapies targeting conditions such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic idiopathic constipation. Founded in 2006, Gelesis is based in Boston, Massachusetts.

Satori Pharmaceuticals is a neuroscience company focused on the discovery and development of disease-modifying therapies for Alzheimer's disease, Parkinson's disease and other neurodegenerative disorders.

Follica, Inc. focuses on developing innovative treatments for hair loss in adults. The company has created a proprietary in-office device that disrupts the skin to stimulate the creation of new hair follicles, as well as an at-home treatment system that delivers therapeutic compounds directly to the scalp for daily use. Incorporated in 2005 and based in Boston, Massachusetts, Follica operates as a subsidiary of PureTech Health plc. The market for hair follicle-related treatments exceeds $10 billion annually, reflecting a significant demand for effective solutions in addressing hair loss disorders.

Follica, Inc. focuses on developing innovative treatments for hair loss in adults. The company has created a proprietary in-office device that disrupts the skin to stimulate the creation of new hair follicles, as well as an at-home treatment system that delivers therapeutic compounds directly to the scalp for daily use. Incorporated in 2005 and based in Boston, Massachusetts, Follica operates as a subsidiary of PureTech Health plc. The market for hair follicle-related treatments exceeds $10 billion annually, reflecting a significant demand for effective solutions in addressing hair loss disorders.

Satori Pharmaceuticals is a neuroscience company focused on the discovery and development of disease-modifying therapies for Alzheimer's disease, Parkinson's disease and other neurodegenerative disorders.

Follica, Inc. focuses on developing innovative treatments for hair loss in adults. The company has created a proprietary in-office device that disrupts the skin to stimulate the creation of new hair follicles, as well as an at-home treatment system that delivers therapeutic compounds directly to the scalp for daily use. Incorporated in 2005 and based in Boston, Massachusetts, Follica operates as a subsidiary of PureTech Health plc. The market for hair follicle-related treatments exceeds $10 billion annually, reflecting a significant demand for effective solutions in addressing hair loss disorders.

Follica, Inc. focuses on developing innovative treatments for hair loss in adults. The company has created a proprietary in-office device that disrupts the skin to stimulate the creation of new hair follicles, as well as an at-home treatment system that delivers therapeutic compounds directly to the scalp for daily use. Incorporated in 2005 and based in Boston, Massachusetts, Follica operates as a subsidiary of PureTech Health plc. The market for hair follicle-related treatments exceeds $10 billion annually, reflecting a significant demand for effective solutions in addressing hair loss disorders.

Gelesis, Inc. is a biotechnology company focused on developing therapies for gastrointestinal-related chronic diseases, particularly obesity and type 2 diabetes. Utilizing a mechanobiology technology platform, Gelesis creates innovative products aimed at weight management. Its lead product, Gelesis100, is an orally administered smart pill composed of hydrogel particles that expand in the gastrointestinal tract, promoting a feeling of fullness and aiding in calorie reduction. This product is designed to be safe, having materials recognized as safe by regulatory authorities. In addition to Gelesis100, the company has a pipeline of potential therapies targeting conditions such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic idiopathic constipation. Founded in 2006, Gelesis is based in Boston, Massachusetts.

Solace Pharmaceuticals, a Boston based drug company focused on therapeutics for chronic pain.

Gelesis, Inc. is a biotechnology company focused on developing therapies for gastrointestinal-related chronic diseases, particularly obesity and type 2 diabetes. Utilizing a mechanobiology technology platform, Gelesis creates innovative products aimed at weight management. Its lead product, Gelesis100, is an orally administered smart pill composed of hydrogel particles that expand in the gastrointestinal tract, promoting a feeling of fullness and aiding in calorie reduction. This product is designed to be safe, having materials recognized as safe by regulatory authorities. In addition to Gelesis100, the company has a pipeline of potential therapies targeting conditions such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic idiopathic constipation. Founded in 2006, Gelesis is based in Boston, Massachusetts.

Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. It was founded in 2005 and headquartered in Cambridge, Massachusetts.

Satori Pharmaceuticals is a neuroscience company focused on the discovery and development of disease-modifying therapies for Alzheimer's disease, Parkinson's disease and other neurodegenerative disorders.